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The development of new blood and lymphatic vessels from preex-
isting ones is recognized as essential for tumor progression and 
metastasis; therefore, angiogenesis inhibition is finding increasing 
application in the clinic. The most studied signaling pathway for 
angiogenesis, and the one to which most of the efforts of the phar-
maceutical industry have been devoted, is that of the vascular   
endothelial  growth  factor  (VEGF)  and  its  receptors,  mainly 
VEGFR2. However, angiopoietins 1 and 2 (Ang1/2) and their   
receptor  Tie2  represent  another  major  tyrosine  kinase-ligand 
system that is fundamental for the regulation of angiogenesis (1,2).
Ang2 is part of the Tie/angiopoeitin signaling pathway involved 
in vascular growth and maturation. In the presence of the Tie2 
agonist Ang1, Ang2 may act as an antagonist, blocking Tie2 sig-
naling, although the actions of the angiopioetins are largely context 
dependent (1,2). Activation of Ang1/Tie2 signaling ensures struc-
tural integrity of mature vessels and protects the endothelium from 
activation  by  cytokines,  whereas  Ang2/Tie2  signaling  promotes 
vascular destabilization and enables VEGF-induced angiogenesis 
(1). Because Ang2 mediates endothelial cell (EC) responsiveness 
to  tumor-derived  cytokines,  its  targeting  has  promising  features   
for antiangiogenic cancer therapy (2). Furthermore, expression of 
Ang2, like that of VEGF, is induced by hypoxia, a hallmark feature 
of most cancers.
Both the VEGF and Ang receptor systems are expressed on ECs. 
Ang2 is primarily produced by ECs and is strongly induced upon EC 
activation, indicating a regulatory role of the local microenviron-
ment (3). However, VEGFs and Ang2 are also expressed by a variety 
of cancer cells (4,5). Tie2 signaling has a key role in lymphangiogen-
esis (1). Thus, both VEGF and Ang systems hold a pivotal interest 
for the control of angiogenesis-associated disease, although develop-
ment of agents targeting the Ang/Tie system lags behind.
Most clinically approved approaches target the main angiogen-
esis axis, VEGF/VEGFR. In 2009, several investigators brought 
up a major caveat in angiogenesis inhibition, which hangs like the 
sword of Damocles over the future of antiangiogenic therapy. The 
groups  of  Oriol  Casanovas  (Catalan  Institute  of  Oncology, 
L’Hospitalet de Llobregat, Spain) and Robert Kerbel (Sunnybrook 
Health  Sciences  Centre,  Toronto,  Canada)  both  found  that   
VEGF-targeted  angiogenesis  inhibition  increased  metastasis  in 
experimental  models  (6,7),  apparently  due  to  hypoxia-induced 
overexpression  of  the  met  axis  components  (8).  Clinicians  have 
not  yet  reported  this  effect,  perhaps  in  keeping  with  the   
vascular normalization hypothesis of Jain (9). However, nearly all 
angiogenesis  inhibitory  therapies  are  approved  for  advanced 
disease. As angiogenesis inhibition moves further up the line in 
therapeutic strategies, theoretically, the risk increases for clinical 
observation of enhancement of metastatic dissemination.
In this issue of the Journal, Holopainen et al. (10) report that 
specific targeting of Ang2 inhibits angiogenesis and metastasis   
in  mouse tumor models (10). Blocking the Ang/Tie2 pathway 
by  bivalent  anti-Ang1/Ang2  antibodies  was  previously  shown   
to curb tumor growth (11). Holopainen et al. (10) show that 
systemic overexpression of Ang2 promotes metastatic dissemina-
tion, whereas specific Ang2 blockade represses it. The authors 
investigated the antimetastatic effects of the Ang2 blockade and 
found that it attenuated tumor lymphangiogenesis and reduced 
tumor cell dissemination into the regional lymph nodes, a major 
route for metastasis. They also found that metastases are associ-
ated with areas of blood vessel disruption, as evidenced by endo-
thelial junctional alterations and detachment from the basement 
membrane. Importantly, the Ang2 blockade reverted these vas-
cular phenotypes that were associated with metastasis.
These data add to a rapidly expanding series of indications that 
targeting Ang2 may be a key alternative (or complementary) 
strategy for counteracting the pro-metastatic activity of certain 
antiangiogenic approaches (6,7). In an independent study, Mazzieri 
et al. (12) recently showed that an Ang2 blockade represses tumor 
angiogenesis and metastasis in mouse models of spontaneous carci-
nogenesis, including metastatic breast cancer (12). In addition to 
direct effects on the tumor blood vessels, these authors focused on 
the role of Ang2 in modulating the activity of proangiogenic Tie2-
expressing  macrophages  (TEMs).  There  is  substantial  evidence 
that TEMs are regulators of tumor angiogenesis in vivo (1) and that 
these cells respond to Ang2 in vitro (13,14). Although TEMs were 
recruited into the tumors, inhibition of Ang2 appeared to interrupt 
a feed-forward loop involving Tie2 upregulation on TEMs that was 
sufficient to interfere with their ability to promote tumor blood 
vessels (12). Whereas both studies (10,12) show that Ang2 blockade 
inhibits dissemination of metastases, Mazzieri et al. (12) also 
found that when performed after tumor cell dissemination, Ang2 
inhibition  could  hinder  further  growth  of  established  metastatic 
nodules. Although Mazzieri et al. (12) did not investigate the mech-
anisms of metastasis inhibition in their study (12), it is possible that 
TEMs  directly  promote  the  growth  of  metastasis  by  inducing   
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angiogenesis.  Further  evidence  for  a  role  of  Ang2  in  metastatic 
dissemination  comes  from  its  association  with  metastasis  and 
chronic inflammation, another hallmark of cancer, in a chemical 
carcinogenesis model (15).
Our views on metastasis are undergoing rapid evolution, if not 
a  complete  revolution  (8).  While  the  role  of  EC  disruption  in 
mediating metastatic dissemination seems intuitive, an important 
role  of  myeloid  cells  is  being  uncovered  (16–18).  Tumor-
infiltrating myeloid cells promote tumor cell intravasation, dis-
semination,  and  metastasis  (16,17).  Furthermore,  they  are 
increasingly linked to the formation of the “pre-metastatic niche,” 
a local microenvironment induced by the primary tumor before 
the  arrival  of  metastatic  cells  to  the  distant  organ  (19).  Ang2-
mediated EC destabilization and TEM activation may have a key 
role in the formation of the pre-metastatic niche (20). Future chal-
lenges include understanding the role of TEMs in building and 
modulating the pre-metastatic niche and the role of Ang2 effects 
on ECs for recruitment and activation of myeloid cells. Together, 
these novel findings suggest that the production of VEGF and 
Ang2 by tumors has both local and systemic effects (Figure 1). 
Local effects of Ang2 include promotion of lymphangiogenesis 
and  lymphatic  tumor  cell  dissemination  (10),  whereas  systemic 
Ang2  effects  may  involve  the  “preparation”  of  pre-metastatic 
niches. In addition, Ang2 inhibition appears to prevent myeloid-
mediated  angiogenesis  (12),  a  main  mechanism  of  resistance 
(21,22).
Holopainen et al. (10) also show that blocking Ang2 inhibits 
developmental retinal vascularization. This suggests that Ang2 may 
be an interesting target in other angiogenesis-associated diseases, 
including ocular and cardiovascular diseases.
From a clinical point of view, one wonders if Ang2 blockade can 
alleviate  the  concerns  of  hypoxia-induced  metastatic  dissemina-
tion.  Given  the  context-dependent  functions  of  Angs,  several 
Figure 1. Hypothetical roles of Ang2 in metastasis and the pre-metastatic 
niche  based  on  recent  studies  and  the  effects  of  Ang2  blockade  on   
dissemination and development of metastasis. Ang2 = angiopoeitin 2; 
TEM  =  Tie2-expressing  macrophage;  Tie2  =  tyrosine  kinase  with 
immunoglobulin  and  epidermal  growth  factor  homology  domains; 
VEGF = vascular endothelial growth factor.
points still need to be investigated: 1) Would blocking Ang2 alone 
be more advantageous than blocking both Ang1 and Ang2, the 
current main strategy of the few clinical trials? 2) Should we block 
only Ang2 or both Ang2 and VEGF? 3) Would Tie2 inhibition by 
small molecule inhibitors be a “risky business” or an ideal strategy? 
4) When should anti-Ang2 treatment start to efficiently block 
metastasis?
Finally, the majority of current antimetastatic drug studies 
are conducted using cultured tumor cells and preclinical models, 
measuring the capability to impair growth or invasion in vitro, to 
reduce tumor growth or prevent metastasis in vivo. However, 
with standard approaches to clinical trials, although we can study 
drugs able to reduce tumor size and/or metastatic burden, it is 
difficult to study drugs that prevent metastasis. With our current 
clinical  trial  designs,  it  is  likely  that  many  potentially  useful 
“purely”  antimetastatic  drugs  have  been  overlooked  or  dis-
carded.  In  our  view,  targeting  Ang2/Tie2  deserves  additional 
attention for further therapeutic development in adequate clin-
ical trials.
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